273 related articles for article (PubMed ID: 29089464)
1. Correlations of
Ma SJ; Liu YM; Zhang YL; Chen MW; Cao W
Biosci Rep; 2018 Feb; 38(1):. PubMed ID: 29089464
[TBL] [Abstract][Full Text] [Related]
2. Correlation between a variable number tandem repeat (VNTR) polymorphism in SMYD3 gene and breast cancer: A genotype-phenotype study.
Al-Eitan LN; Rababa'h DM
Gene; 2020 Feb; 728():144281. PubMed ID: 31836525
[TBL] [Abstract][Full Text] [Related]
3. SET and MYND Domain-Containing Protein 3 (SMYD3) Polymorphism as a Risk Factor for Susceptibility and Poor Prognosis in Ovarian Cancer.
Liu TT; Xu H; Gao WP; Zhang SX; Zhou XH; Tang J; Liu QN
Med Sci Monit; 2016 Dec; 22():5131-5140. PubMed ID: 28024138
[TBL] [Abstract][Full Text] [Related]
4. EZH2 genetic variants affect risk of gastric cancer in the Chinese Han population.
Zhou Y; Du WD; Wu Q; Liu Y; Chen G; Ruan J; Xu S; Yang F; Zhou FS; Tang XF; Tang HY; Zuo XB; Zhang FY; Sun LD; Zhang XJ
Mol Carcinog; 2014 Aug; 53(8):589-97. PubMed ID: 22228224
[TBL] [Abstract][Full Text] [Related]
5. The SMYD3 VNTR 3/3 polymorphism confers an increased risk and poor prognosis of hepatocellular carcinoma in a Chinese population.
Li RD; Tang YH; Wang HL; Yang D; Sun LJ; Li W
Pathol Res Pract; 2018 May; 214(5):625-630. PubMed ID: 29691085
[TBL] [Abstract][Full Text] [Related]
6. A genetic variant in p63 (rs17506395) is associated with breast cancer susceptibility and prognosis.
Zhang N; Huo Q; Wang X; Chen X; Long L; Guan X; Jiang L; Ma T; Hu W; Yang Q
Gene; 2014 Feb; 535(2):170-6. PubMed ID: 24316488
[TBL] [Abstract][Full Text] [Related]
7. SMYD3 overexpression was a risk factor in the biological behavior and prognosis of gastric carcinoma.
Liu Y; Luo X; Deng J; Pan Y; Zhang L; Liang H
Tumour Biol; 2015 Apr; 36(4):2685-94. PubMed ID: 25472580
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of SMYD3 and matrix metalloproteinase-9 are associated with poor prognosis of patients with gastric cancer.
Liu Y; Liu H; Luo X; Deng J; Pan Y; Liang H
Tumour Biol; 2015 Jun; 36(6):4377-86. PubMed ID: 25627005
[TBL] [Abstract][Full Text] [Related]
9. SMYD3 regulates gastric cancer progression and macrophage polarization through EZH2 methylation.
Wang P; Zhao L; Rui Y; Ding Y
Cancer Gene Ther; 2023 Apr; 30(4):575-581. PubMed ID: 36127410
[TBL] [Abstract][Full Text] [Related]
10. Association of Enhancer of Zeste 2 (EZH2) Genotypes with Bladder Cancer Risk in Taiwan.
Chang WS; Liao CH; Tsai CW; Hu PS; Wu HC; Hsu SW; Hsiao CL; Hsu CH; Hung YW; Bau DT
Anticancer Res; 2016 Sep; 36(9):4509-14. PubMed ID: 27630289
[TBL] [Abstract][Full Text] [Related]
11. Upregulation of SMYD3 and SMYD3 VNTR 3/3 polymorphism increase the risk of hepatocellular carcinoma.
Binh MT; Hoan NX; Giang DP; Tong HV; Bock CT; Wedemeyer H; Toan NL; Bang MH; Kremsner PG; Meyer CG; Song LH; Velavan TP
Sci Rep; 2020 Feb; 10(1):2797. PubMed ID: 32071406
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic-related gene expression profile in medullary thyroid cancer revealed the overexpression of the histone methyltransferases EZH2 and SMYD3 in aggressive tumours.
Sponziello M; Durante C; Boichard A; Dima M; Puppin C; Verrienti A; Tamburrano G; Di Rocco G; Redler A; Lacroix L; Bidart JM; Schlumberger M; Damante G; Russo D; Filetti S
Mol Cell Endocrinol; 2014 Jul; 392(1-2):8-13. PubMed ID: 24813658
[TBL] [Abstract][Full Text] [Related]
13. Elevated Levels of SET and MYND Domain-Containing Protein 3 Are Correlated with Overexpression of Transforming Growth Factor-β1 in Gastric Cancer.
Liu H; Liu Y; Kong F; Xin W; Li X; Liang H; Jia Y
J Am Coll Surg; 2015 Aug; 221(2):579-90. PubMed ID: 26077602
[TBL] [Abstract][Full Text] [Related]
14. Prognostic impact of polymorphism of matrix metalloproteinase-2 and metalloproteinase tissue inhibitor-2 promoters in breast cancer in Tunisia: case-control study.
Ben Néjima D; Ben Zarkouna Y; Gammoudi A; Manai M; Boussen H
Tumour Biol; 2015 May; 36(5):3815-22. PubMed ID: 25656607
[TBL] [Abstract][Full Text] [Related]
15. Expression of enhancer of zeste homolog 2 correlates with survival outcome in patients with metastatic breast cancer: exploratory study using primary and paired metastatic lesions.
Inari H; Suganuma N; Kawachi K; Yoshida T; Yamanaka T; Nakamura Y; Yoshihara M; Nakayama H; Yamanaka A; Masudo K; Oshima T; Yokose T; Rino Y; Shimizu S; Miyagi Y; Masuda M
BMC Cancer; 2017 Feb; 17(1):160. PubMed ID: 28241804
[TBL] [Abstract][Full Text] [Related]
16. High immunoexpression of Ki67, EZH2, and SMYD3 in diagnostic prostate biopsies independently predicts outcome in patients with prostate cancer.
Lobo J; Rodrigues Â; Antunes L; Graça I; Ramalho-Carvalho J; Vieira FQ; Martins AT; Oliveira J; Jerónimo C; Henrique R
Urol Oncol; 2018 Apr; 36(4):161.e7-161.e17. PubMed ID: 29174711
[TBL] [Abstract][Full Text] [Related]
17. P27 V109G Polymorphism is associated with lymph node metastases but not with increased risk of breast cancer.
Naidu R; Har YC; Taib NA
J Exp Clin Cancer Res; 2007 Mar; 26(1):133-40. PubMed ID: 17550142
[TBL] [Abstract][Full Text] [Related]
18. A functional HOTAIR rs12826786 C>T polymorphism is associated with breast cancer susceptibility and poor clinicopathological characteristics in a Turkish population: a hospital-based case-control study.
Bayram S; Sümbül AT; Dadaş E
Tumour Biol; 2016 Apr; 37(4):5577-84. PubMed ID: 26577852
[TBL] [Abstract][Full Text] [Related]
19. Synergistic triad epistasis of epigenetic H3K27me modifier genes, EZH2, KDM6A, and KDM6B, in gastric cancer susceptibility.
Lee SW; Park DY; Kim MY; Kang C
Gastric Cancer; 2019 May; 22(3):640-644. PubMed ID: 30374835
[TBL] [Abstract][Full Text] [Related]
20. The MMP-2 -735 C allele is a risk factor for susceptibility to breast cancer.
Yari K; Rahimi Z; Moradi MT; Rahimi Z
Asian Pac J Cancer Prev; 2014; 15(15):6199-203. PubMed ID: 25124598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
